EyePoint reports inducement grants under NASDAQ listing rule

EyePoint Pharmaceuticals announced that the Company granted non-statutory stock options to new employees as inducement awards outside the Company’s 2016 Long-Term Incentive Plan in accordance with NASDAQ Listing Rule 5635(c)(4). The Company granted stock options to purchase up to an aggregate of 6,000 shares of EyePoint Pharmaceuticals common stock to two new employees. The stock options were granted on February 15, 2023. The grants were approved by the Compensation Committee and made as an inducement material to each employee entering into employment with EyePoint Pharmaceuticals in accordance with NASDAQ Listing Rule 5635(c)(4). The option awards have an exercise price of $3.70 per share, the closing price of EyePoint Pharmaceuticals’ common stock on February 15, 2023.